News
PROK
1.600
-4.76%
-0.080
Weekly Report: what happened at PROK last week (0914-0918)?
Weekly Report · 4d ago
Weekly Report: what happened at PROK last week (0907-0911)?
Weekly Report · 09/14 10:28
Weekly Report: what happened at PROK last week (0831-0904)?
Weekly Report · 09/07 10:21
Weekly Report: what happened at PROK last week (0824-0828)?
Weekly Report · 08/31 10:29
Weekly Report: what happened at PROK last week (0817-0821)?
Weekly Report · 08/24 10:30
ProKidney Insider Makes a Big Move With Major Stock Sale
TipRanks · 08/21 02:02
Weekly Report: what happened at PROK last week (0810-0814)?
Weekly Report · 08/17 10:31
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
Seeking Alpha · 08/14 19:36
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
TipRanks · 08/13 13:40
ProKidney (PROK) Receives a Hold from Morgan Stanley
TipRanks · 08/11 12:55
ProKidney (PROK) Gets a Buy from Guggenheim
TipRanks · 08/11 11:16
Analysts’ Opinions Are Mixed on These Healthcare Stocks: ProKidney (PROK), Crinetics Pharmaceuticals (CRNX) and Alumis Inc. (ALMS)
TipRanks · 08/11 10:30
Bank of America Securities Keeps Their Sell Rating on ProKidney (PROK)
TipRanks · 08/11 09:16
ProKidney GAAP EPS of -$0.15 misses by $0.01, revenue of $0.15M in-line
Seeking Alpha · 08/10 20:54
Weekly Report: what happened at PROK last week (0803-0807)?
Weekly Report · 08/10 10:25
Weekly Report: what happened at PROK last week (0727-0731)?
Weekly Report · 08/03 10:25
Weekly Report: what happened at PROK last week (0720-0724)?
Weekly Report · 07/27 10:29
Weekly Report: what happened at PROK last week (0713-0717)?
Weekly Report · 07/20 10:25
As Q2 earnings kick off, these small-cap stocks earn an A+ for profitability
Seeking Alpha · 07/17 17:06
Weekly Report: what happened at PROK last week (0706-0710)?
Weekly Report · 07/13 10:28
More
Webull provides a variety of real-time PROK stock news. You can receive the latest news about ProKidney through multiple platforms. This information may help you make smarter investment decisions.
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.